Abuse-resistant pharmaceutical composition for the treatment of opioid dependence
AssigneeOrexo AB
InventorAndreas Fischer
Life of this patent
Estimating the term…
Abstract
There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.
Claims21
A pharmaceutical composition in the form of a tablet suitable for sublingual administration, which comprises:
- buprenorphine or a pharmaceutically acceptable salt thereof provided in the form of microparticles,
- particles comprising a weakly acidic material, which weakly acidic material is citric acid, or particles comprising weakly-acidic buffer-forming materials, which weakly-acidic buffer-forming materials are citric acid and sodium citrate,
- which microparticles of buprenorphine or salt thereof are, at least in part, in contact with the particles comprising citric acid and/or sodium citrate,
- naloxone or a pharmaceutically acceptable salt thereof, and
- a disintegrant,
- wherein the dose ratio of buprenorphine to naloxone (calculated as the free bases) is about 4:1.
Dependencies are inferred from the claim text.